Thanks, Steve.
will the live. XXX contracted five quarter, our revenue-generating of In installed company quickly turn Pheno Pheno base priorities. the quarter and and instruments commentary results of a brought We to U.S. ended implementation. a fourth another our three backlog the instruments quarter instruments, new with fourth my pending cover I Pheno instruments and XX
not fourth expectations. our commercial meet While quarter results did our
our As given mentioned our partnership. setting remain BD last team we the last built on and call, strong We commercial up the restructured momentum turned success. encouraged year BD to late for being our focus with commercial
like market and advancing want I partnership delivering financial financial by an an strategic on strength, provide Wave. I update priorities would innovation Starting on with provide three our update debt on our growth to Dickinson strength, Now share Becton important through to restructuring.
and know, XX. which may ad hoc this group effective became matured XX became agreement on notes notes, X, and the convertible due we of the into X.X% a an you March trustee on our holders On forbearance notes of year. entered March senior approximately and with XX% outstanding March of payable As of
agreement, trustee holders forbearance and directed to the to of in with until under and forbear the connection events their certain under XX. the March default the exercising from -- indenture indenture Pursuant the revenues agreed rights the
to work of to the to facilitate those notes and continue agreed have the other extension the an stakeholders of and with continued forbearance holders We key period discussions.
Becton Pheno Dickinson share next priority, Arc with through growing partnership. our to our Moving and market
of in announced a BD quarter, globally. Dickinson. partnership an As thousands the most countries formation with Becton spanning reminder, microbiology customers commercial global of with global exclusive we the is last leader
Activities BD of of lab world quarter sales in on the commercial susceptibility with training evidence and positive blood processes time rapid clinical proven BD's necessary joint a spent every into was sales Much Nearly one uses combining our culture products. organizations. clinical our train taking the of the body of value single least included at microbiology the process. to the
the successfully targeted culture specimen finally, faster combating to samples antimicrobial This with bloodstream product for and end-to-end AXDX we and reporting through growth physicians. infections detection identification of blood testing pharmacists of positive BD product susceptibility collection therapies Together, combined and launched offering and enables workflow end-to-end our microbiology complete only portfolios. from to and
This combat and unique the are to for the our and principal is BD. burden portfolios with growing joining within truly There together value exciting antimicrobial clinical three resistance. sepsis drivers us rationale proposition bringing microbiology forces for
ensure in our commercial significantly by U.S., the to collaborate our partnership our commercial to both aligning in commercial launched our future U.S. reach innovation. offerings with second, improve on teams combining we fourth to effectiveness reach, selling both our portfolio; and we improve our quarter lastly, selling after abroad; spending and year, the of the January to sales First, marketing and improve effectiveness. BD's In and this
encouraging reach is strengthening. our which commercial launch, Since indication of has our increased, sales an activity dramatically is
increase we QX far from quarter a new funnel thus XXX% in Specifically, the fourth opportunities in sales saw versus XXXX. of our
new is into focus. Pheno we our We joint sales our sales are year, ahead plan of our and a bringing this target funnel second have Improving significant effectiveness thus tracking opportunities of far.
and implementations. joint territory and key roles responsibilities the highlights funnel and to process winning between specialists more managers faster Our our accounts Pheno sales meaningful clinical BD progression, drive
sales highly joint improved economics delivering strong marketing, and customized synergies across on workflow are contracting focused solutions. our infection processes Our deal bloodstream offering by
progress We of allows evaluate and rapid many a existing U.S. part customers an are have 'XX, example, we BD and in meaningful program, date, the can For driving which our susceptibility. opportunities the quite In done. summary, will the systems we of but renewal current early from close new and anticipate market second as work customers share XXXX, still in there's enthusiastic renew Pheno and to the implement early active half to growth. to for be of
and month. EMEA partnership this EMEA, launched delivery we access market -- system healthcare is country-by-country commercial logistical our requiring In more complex considerations. a system
For as and Nordic serve such team's by a This adapting launching Germany early but days. which and we acquisition the the the are tender-driven countries. are example, led our and playbook to such commercial U.K., we delay encouraged to in the as markets capital from progress slight enthusiasm differ in markets abroad, Italy
commercializing in are and EMEA, workflow bloodstream both infections. We automated and in more thus even bringing Arc to combat cost-effective solution Pheno
in study an a publishing journal. readout upcoming abstract and evaluation the European An in during be author local Arc will site presenting be the full Italian a will ASM June,
We will for efforts peer-reviewed the future. our EMEA publication be selling in leveraging this in
see U.S. eager to Arc with are the We for strong in and to our approval. bring U.S. demand continue the to market FDA after learnings commercial Arc
cost-effective is gain market to to U.S. for access eager solution preparation positive automated sample an The cultures. blood
Arc with As we pursue continue discussed the as II on Class XXX(k) them. FDA to dialogue device with a active prior our calls, remain in and
U.S. in QX. will We we forecasted clinical which not date have expected begin is in launch trials, a the until
begin with BD will future we developments. product partnership, to collaborate Lastly, our on
of good is for for workflow upfront colony cultures off summary, our is blood area first a In The and streamlining positive our start. isolated work with BD focus samples. to Wave
and engagement in focus organizations. our both U.S. the have with launched EMEA joint and customer strong commercial from We
our Now next-generation delivering to third strategic our priority, with platform, Wave. turning comments my innovation
make We with continue very progress to good program. Wave our development
taken of exciting has we delivery over is previously, which core alpha significantly As our efforts. very discussed XX in are running This sped up and and up laboratory. development our have instruments,
be over reminder, blood colony platform culture will improved provide positive results able to Pheno. and on rapid a both with the platform system Wave a significantly samples As test susceptibility economics isolated for single
approach confirmed Our traditional will on market superior the isolate-based consolidated advantage platforms have susceptibility have a customers a over today.
expands share restating and economics. Wave while Accelerate, wallet significantly platform our For customer per our revenue
I we financial thank delivering his complete start the by advancing clinical to shortly Wave. note, service personal is as market to CFO. of Becton data In with our the target summary, of strategic growing to further wanted market Our trials recognize On Steve and by innovation three will be share a take Reichling to on building priorities; our for on looking preclinical readout opportunity strength; years and and Dickinson; details thereafter. have the update with our the year end
look to advisory an I capacity. with continuing work forward Steve to in
questions have and David from meeting a he to would know takes investors@axdx.com. our to I questions addressed, to not great others David now happy in Should send have for would for be as new I our request or call forward, on Thank confidence questions you everyone we welcome answer analysts. CFO, Patience you. look Steve. as follow-up these getting to over to the Moving forward
